Pharmaceutical Executive-09-01-2016

Pharm Exec’s 9th annual list of rising industry leaders illustrates how the deployment of essential human capital has changed in line with a business model that is no longer static and predictable-or complacent.

Pharm Exec sits down with UBC President Patrick Lindsay to provide some real-world context around our 2016 feature profile of sixteen Emerging Leaders in biopharma.

Pharm Exec and inVentiv Health convened a roundtable discussion at the 2016 ASCO meeting to review the use of patient-reported outcomes (PRO) in the clinical trial and commercialization space.

Big pharma has become increasingly vulnerable to larger geopolitical and macroeconomic risks-a realization that has slowly creeped into their business planning.

Traditional sales and pricing practices face legal challenges and political backlash.

A new campaign in France hopes to build on the nation’s legacy as a life sciences innovator, through championing a fresh pathway to success in areas such as preventative healthcare, advanced diagnostics, medical devices, home care, and big data.

Click the title above to open the Pharmaceutical Executive September 2016 issue in an interactive PDF format.